Medy-Tox Inc (086900) - Total Assets
Based on the latest financial reports, Medy-Tox Inc (086900) holds total assets worth ₩586.91 Billion KRW (≈ $397.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Medy-Tox Inc net assets for net asset value and shareholders' equity analysis.
Medy-Tox Inc - Total Assets Trend (2013–2024)
This chart illustrates how Medy-Tox Inc's total assets have evolved over time, based on quarterly financial data.
Medy-Tox Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Medy-Tox Inc's total assets of ₩586.91 Billion consist of 30.3% current assets and 69.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩45.65 Billion | 7.5% |
| Accounts Receivable | ₩53.88 Billion | 8.8% |
| Inventory | ₩64.26 Billion | 10.5% |
| Property, Plant & Equipment | ₩200.27 Billion | 32.6% |
| Intangible Assets | ₩63.89 Billion | 10.4% |
| Goodwill | ₩8.14 Billion | 1.3% |
Asset Composition Trend (2013–2024)
This chart illustrates how Medy-Tox Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 086900 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medy-Tox Inc's current assets represent 30.3% of total assets in 2024, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, up from 5.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is property, plant & equipment at 32.6% of total assets.
Medy-Tox Inc Competitors by Total Assets
Key competitors of Medy-Tox Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Medy-Tox Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.35 | 1.18 |
| Quick Ratio | 1.30 | 0.81 | 0.86 |
| Cash Ratio | 0.00 | 0.23 | 0.00 |
| Working Capital | ₩75.11 Billion | ₩42.24 Billion | ₩21.12 Billion |
Medy-Tox Inc - Advanced Valuation Insights
This section examines the relationship between Medy-Tox Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.6% |
| Total Assets | ₩615.16 Billion |
| Market Capitalization | $470.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medy-Tox Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Medy-Tox Inc's assets grew by 0.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medy-Tox Inc (2013–2024)
The table below shows the annual total assets of Medy-Tox Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩615.16 Billion ≈ $416.89 Million |
+0.58% |
| 2023-12-31 | ₩611.62 Billion ≈ $414.49 Million |
+2.57% |
| 2022-12-31 | ₩596.29 Billion ≈ $404.10 Million |
+3.22% |
| 2021-12-31 | ₩577.70 Billion ≈ $391.50 Million |
+23.50% |
| 2020-12-31 | ₩467.76 Billion ≈ $317.00 Million |
+10.97% |
| 2019-12-31 | ₩421.53 Billion ≈ $285.66 Million |
+6.71% |
| 2018-12-31 | ₩395.01 Billion ≈ $267.70 Million |
+3.69% |
| 2017-12-31 | ₩380.95 Billion ≈ $258.16 Million |
+17.56% |
| 2016-12-31 | ₩324.03 Billion ≈ $219.59 Million |
+59.19% |
| 2015-12-31 | ₩203.55 Billion ≈ $137.94 Million |
+20.79% |
| 2014-12-31 | ₩168.51 Billion ≈ $114.20 Million |
+112.19% |
| 2013-12-31 | ₩79.41 Billion ≈ $53.82 Million |
-- |
About Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more